Syntheses of novel tetra-and penta-cyclic benzopyran and pyridopyran derivatives, via direct intramolecular arylation of 2-iodophenoxymethylhetarenes and 3-(2-bromo-pyridin-3-yloxymethyl)-benzo [4, 5] 
Introduction
Pyrans and their benzo derivatives are of interest as biologically active compounds. [1] [2] [3] The synthesis and reactions of pyrans and benzopyrans have been well reviewed. [4] [5] [6] [7] [8] [9] Recently the uses and properties of important natural and synthetic 2H-pyran-2-ones in organic synthesis were documented. 8, 9 One of the earliest works describing the synthesis of the pyranothiazole ring from 3,5-dibromopyran-4-one and a thioamide was published in 1948. 10 Some methods for the preparation of 2-substituted [1] benzopyrano [3,4-d] -thiazol-4-ones and -imidazol-4-ones are documented. 11 More recently, the palladium-catalyzed synthesis of thiazolobenzopyran-2-ones from methyl 5-(2-allyloxyphenyl)thiazole-4-carboxylates was reported. 12 Benzopyranothiazole and benzopyranothiophene ring systems were prepared by thermal intramolecular 1,3-dipolar cycloaddition of 2-(prop-2-ynyloxy-and cyanomethyloxy)-3,5-diphenyl-4-hydroxythiazolium hydroxides. 13 Benzopyranoimidazoles have been prepared by electrochemical reduction / rearrangement of benzopyranotriazines 14 or by condensation of hydrazine with 4-oxochroman-3-carbaldehyde 15 . An important modern development in the palladium-catalyzed synthesis of heterocyclic compounds using an intramolecular Heck-type reaction was recently highlighted in some reviews. [16] [17] [18] [19] Regioselective functionalization of the imidazole ring by transition metal-catalyzed C-N and C-C bond formation was reported in details by Rossi et al. 20 Interestingly, that the pyrano[3′,4′:4,5]imidazo[1,2-a]pyridin-1-one ring system has been constructed by Cu(I)-catalyzed cross-coupling and heterocyclization reactions of halogenated imidazopyridinecarboxylic acids in the presence of terminal alkynes. 21 Our interest in polycyclic compounds containing imidazothiazole and related fragments was prompted by the wide range of biological activity of these heterocyclic systems. [22] [23] [24] Furthermore, the synthesis of tetra-and penta-cyclic imidazolo-and thiazolo-benzopyran derivatives has not been investigated until now and so is the main aim of the present work. Beside this, selected stable compounds (4a, 10 and 13) were tested as cytotoxic agents.
Results and Discussion
Synthesis of the novel polycyclic compounds 4a,b, 7, 10 and 13 was carried out in two steps. Alkylation of 2-iodophenol (2a) or 2-bromo-3-hydroxypyridine (2b) with chloromethylhetarenes 1, 5, 8, 11 24 was successfully achieved under phase transfer catalytic conditions -solid KOH / 18-crown-6 / toluene. Intermediates 3a,b, 6, 9 and 12 were isolated in 21-87 % yields. (Schemes 1-4)
Scheme 1
The influence of catalyst, ligand and additive on the intramolecular Heck-type cyclization was studied in detail. Initially, we examined direct intramolecular arylation of 2-iodophenoxymethylhetarene 3a using 10 mol.% Pd(PPh3)4 as catalyst and 2 eq. Cs2CO3 as base. No product was found under these conditions. The use of the system 10 mol.% Pd(OAc)2 / 20 mol.% Xantphos / Cs2CO3 (2 eq.) / toluene provided the polycycle 4a in a low (17%) yield with 55% conversion. The high activity of Ag2CO3 as an additive in Rh-catalyzed arylation of hetarenes was recently demonstrated. 25 The addition of 0.5 eq. Ag2CO3 to the system Pd(OAc)2 (10 mol.%) / Xantphos (20 mol.%) / Cs2CO3 (2 eq.) / toluene furnished the desired product 4a in improved (69 %) yield with full conversion of the starting material 3a. All catalytic systems in the presence of Ag2CO3 were more active.
The polycycle 4a was also obtained directly from 3-chloromethylbenzo [4, 5] imidazo [2,1-b] thiazole (1) and 2-iodophenol (2a) in a one-pot synthesis using the bicatalytic system Pd(OAc)2 (10 mol.%) / Xantphos (20 mol.%) / Cs2CO3 (3 eq.) / Ag2CO3 (0,5 eq.) / 18-crown-6 (10 mol.%), but in lower yield (25%) than the two step synthesis provided.
The catalytic system Pd(OAc) 2 (10 mol.%) / Xantphos (20 mol.%) / Cs 2 CO 3 (2 eq.) / Ag 2 CO 3 (0,5 eq.) / toluene, as the most active, was used for the preparation of the polycyclic compounds 4b (Scheme 1), 7 (Scheme 2), 10 (Scheme 3) and 13 (Scheme 4). The products 4a,b, 7, 10 and 13 were isolated by column chromatography in 31-63% yields.
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Scheme 4
The structure of compound 13 was confirmed by X-ray structural data. Needle like crystals of compound 13 suitable for intensity measurement were grown from chloroform. The entire molecule of polycycle 13 is essentially planar (Figure 1 ). The maximal deviation from the least squares mean plane drawn through all non-hydrogen atoms of the molecule is 0.398 (2) Cytotoxic activity of compounds 19 and 23 was tested in vitro on two monolayer tumor cell lines: MG-22A and HT-1080 (Table 2) . Compound 4a exhibit high activity on the mouse hepatoma (MG-22A, 6 μg/mL) cancer cell line. However, on the human fibrosarcoma cell line this compound is essentially inactive. Polycyclic compound 10 exhibit middle activity on both cancer cell lines. Compound 13 is inactive on the MG-22A and HT-1080 cancer cell lines. Interestingly, that toxicity of compounds 4a, 10 and 13 (LD50, 1058-1487 mg/kg) detected on the mouse normal fibroblasts is not high.
Conclusions
In summary, we have developed a facile method for synthesis of novel imidazole and thiazole containing benzopyran and pyridopyran derivatives via intramolecular cyclization of corresponding 2-iodophenoxy(or bromopyridin-3-yloxy)methylhetarenes in the catalytic system Pd(OAc)2 / Xantphos / Cs2CO3 / Ag2CO3 / toluene. 12H- [1] Benzopyrano[3′,4′:4,5]thiazolo[3,2-a]benzimidazole (4a) exhibit high cytotoxicity on the mouse hepatoma (MG-22A, 6 μg/mL) cancer cell line and low toxicity on mouse Swiss Albino embryo fibroblasts (3T3, LD50 1058 mg/kg).
Experimental Section
General.
1 H and 13 C NMR spectra were recorded on a Varian Mercury BB 400 MHz in CDCl3 using HMDSO as internal standard. LC-MS spectra were recorded on Alliance Waters 2695 instrument and Waters 3100 mass detector. Column chromatography was performed with silica gel 0,035-0,070 nm (Acros). X-Ray diffraction data was collected using Nonius KappaCCD single crystal diffractometer (Bruker AXS) (MoKα 1 -radiation, graphite monochromator). The structure was solved by SIR2004 28 and refined by SHELXL97 (11) were obtained by the procedure described in article. 24 All prepared compounds are new and were characterized by melting point, LC-MS, HRMS, 1 H NMR and 13 C NMR spectra.
General procedure for synthesis of 2-iodophenoxymethylhetarenes 3a, 6, 9, 12 and 3-(2-bromopyridin-3-yloxymethyl)-benzo[4,5]imidazo[2,1-b]thiazole (3b)
Solid pulverized KOH (0.98 g, 4.5 mmol) was added to solution of chloromethyl derivatives 1, 5, 8 or 11 (4 mmol), 2-iodophenol (2a) (0.88 g, 4 mmol) or 2-bromo-3-hydroxypyridine (2b) (0.87 g, 4 mmol), 18-crown-6 (0.1g, 0.4 mmol) in toluene (20 mL). Reaction mixture was refluxed for 2 h, cooled to room temperature, filtered and solvent was removed under reduced pressure. The products were purified using flash chromatography (silica, ethyl acetate). Spectroscopic characteristics. In vitro cytotoxicity assay. Monolayer tumor cell lines -HT-1080 (human fibrosarcoma), MG-22A (mouse hepatoma), 3T3 (mouse Swiss Albino embryo fibroblasts), -were cultured in standard medium (Dulbecco`s modified Eagle`s medium; DMEM) and supplemented with 10% fetal bovine serum ("Sigma"). Tumor cell lines were obtained from the ATCC. About 10 x10 4 cells ml -1 were placed in 96-well plates immediately after compounds were added to the wells; the volume of each plate was 200 μl. The control cells without test compounds were cultured on separate plate. The plates were incubated for 72h, 37 o C, 5% CO2. The number of surviving cells was determined using tri(4-dimethylaminophenyl)methyl chloride (crystal violet: CV) or 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolinium bromide (MTT) 30, 31 . LD50 was tested according "Alternative Toxicological Methods". 32 The program Graph Pad Prism ® 3.0 was used for calculations (r < 0.05.).
3-(2-Iodophenoxymethyl)-benzo[4,5]imidazo[2,1-b]thiazole (3a
